Company Profile
GeoVax Labs Stock Price, News & Catalysts
- Ticker:
- GOVX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.32 USD (-3.56%)
Close
Last updated: October 1, 2026
10.9M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, GOVX closed down 3.56% at $0.3222. No new same-company headline was identified in the current news window.
Company overview
Vaccine and Immunotherapy Company
GeoVax Labs develops vaccines and cancer immunotherapies using modified vaccinia Ankara vectors and gene-directed therapy. Its portfolio targets emerging infectious diseases and difficult-to-treat solid tumors.
GEO-MVA for Mpox and Smallpox
GEO-MVA is a live, non-replicating MVA vaccine being developed for protection against mpox and smallpox. The program is intended to support public-health preparedness and provide an alternative vaccine option for vulnerable populations.
Immunobridging Regulatory Strategy
Because efficacy trials against smallpox are not feasible, GeoVax plans to compare immune responses generated by GEO-MVA with those from an established vaccine. A successful immunobridging study could support regulatory submissions.
Gedeptin Cancer Gene Therapy
Gedeptin is a gene-directed enzyme prodrug therapy delivered into tumors. It is designed to convert an administered prodrug into an active anticancer agent locally and is being explored with checkpoint inhibition.
MVA Platform Capabilities
The company's MVA technology can deliver multiple antigens in a single vaccine and stimulate both antibody and T-cell responses. Government relationships and external manufacturing partners are important to development and stockpile opportunities.
Future catalysts
- Initiation of the pivotal GEO-MVA immunobridging study in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of GeoVax Labs (GOVX)?
GeoVax Labs (GOVX) most recently closed at 0.32 USD, a -3.56% move versus the previous session.
What is the market cap of GeoVax Labs (GOVX)?
GeoVax Labs currently has a market capitalization of 10.9M USD on BioPharmSignal.
What does GeoVax Labs do?
Vaccine and Immunotherapy Company GeoVax Labs develops vaccines and cancer immunotherapies using modified vaccinia Ankara vectors and gene-directed therapy. Its portfolio targets emerging infectious diseases and difficult-to-treat solid tumors. GEO-MVA for Mpox and Smallpox GEO-MVA is a live, non-replicating MVA vaccine being developed for protection...
On which exchange is GOVX stock listed?
GeoVax Labs (GOVX) is associated with NASDAQ, United States, Biopharma.
What is GEO-MVA?
Initiation of the pivotal GEO-MVA immunobridging study in the fourth quarter of 2026.
Which conditions is GeoVax Labs targeting with GEO-MVA?
GeoVax Labs is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does GeoVax Labs describe recent progress with GEO-MVA?
Initiation of the pivotal GEO-MVA immunobridging study in the fourth quarter of 2026.
What is Vaccine?
Vaccine and Immunotherapy Company GeoVax Labs develops vaccines and cancer immunotherapies using modified vaccinia Ankara vectors and gene-directed therapy.